# AMLAL PHARMACEUTICALS INC: Development of a small molecule radiosensitizer for treatment of brain-metastatic non-small cell lung cancer

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | AMLAL PHARMACEUTICALS INC |
| Location | CINCINNATI, OH |
| Project | Development of a small molecule radiosensitizer for treatment of brain-metastatic non-small cell lung cancer |
| Project number | 1R41CA306622-01 |
| Mechanism | R41 |
| Institute | National Cancer Institute |
| Award | $390,537 |
| Awarded | 2026-09-07 |
| Project period | 2026-09-01 to 2027-08-31 |
| UEI | UQN1CKG4QYL5 |

## Why this score
- Award of $390,537.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11255605). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.